2018
RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB
Armstrong T, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Gilbert M. RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB. Neuro-Oncology 2018, 20: vi241-vi241. PMCID: PMC6217700, DOI: 10.1093/neuonc/noy148.998.Peer-Reviewed Original ResearchDose-dense temozolomideObjective responseClinical benefitRecurrent ependymomaAdult clinical trialsModerate-severe painStable disease rateStandard salvage regimenPhase II studyRole of chemotherapyProgression-free survivalDisease-related symptomsDaily lapatinibMedian KPSMedian PFSPFS ratesPrior relapseSalvage regimenAutonomic dysfunctionFree survivalPrimary endpointRecurrent diseaseAdult patientsCombination regimenII study
2014
AT-07A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL
Armstrong T, Vera-Bolanos E, Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Mendoza T. AT-07A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL. Neuro-Oncology 2014, 16: v9-v9. PMCID: PMC4217844, DOI: 10.1093/neuonc/nou237.7.Peer-Reviewed Original ResearchDose-dense temozolomideProgression-free survivalSymptom burdenClinical trialsDisease progressionRecurrent ependymomaFirst prospective clinical trialMedian progression-free survivalPatient Reported Outcome MeasuresPhase II studyOverall symptom burdenProspective clinical trialsPrimary CNS tumorCycle 6Majority of symptomsDry mouthFree survivalPrimary endpointRecurrent diseaseSymptom benefitCNS tumorII studyTreatment courseSymptom interferenceVision changesCurrent Role of Anti-Angiogenic Strategies for Glioblastoma
Thomas AA, Omuro A. Current Role of Anti-Angiogenic Strategies for Glioblastoma. Current Treatment Options In Oncology 2014, 15: 551-566. PMID: 25173555, DOI: 10.1007/s11864-014-0308-2.Peer-Reviewed Original ResearchConceptsProgression-free survivalPhase III trialsIII trialsOverall survivalRecurrent diseaseStandard chemoradiotherapyClinical benefitAnti-vascular endothelial growth factor monoclonal antibodyCognitive declineSimilar progression-free survivalToxicity of bevacizumabAddition of bevacizumabPhase II trialSevere neurologic symptomsFactor monoclonal antibodyNew drug combinationsAnti-angiogenic therapyReduced vascular permeabilityQuality of lifeUnquestionable clinical benefitObserved cognitive declineBevacizumab armOS trendsCorticosteroid useFree survivalMethotrexate re-challenge for recurrent primary central nervous system lymphoma
Pentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalPrognosisRetreatmentRetrospective StudiesSalvage TherapyTreatment OutcomeConceptsPrimary CNS lymphomaKarnofsky performance scoreProgression-free survivalInitial diagnosisRecurrent primary central nervous system lymphomaPrimary central nervous system lymphomaMedian Karnofsky performance scoreMedian progression-free survivalCentral nervous system lymphomaObjective response rateNervous system lymphomaMedian OSCNS lymphomaFree survivalRecurrent diseaseSalvage treatmentFirst relapsePartial responsePCNSL patientsPrognostic factorsComplete responseMedian ageSystem lymphomaDisease relapseMedian time
2008
Primary CNS lymphoma with intraocular involvement
Grimm S, McCannel C, Omuro A, Ferreri A, Blay J, Neuwelt E, Siegal T, Batchelor T, Jahnke K, Shenkier T, Hall A, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto F, Abrey L. Primary CNS lymphoma with intraocular involvement. Neurology 2008, 71: 1355-1360. PMID: 18936428, PMCID: PMC4109164, DOI: 10.1212/01.wnl.0000327672.04729.8c.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaOverall survivalOcular therapyIntraocular involvementCNS lymphomaCSF cytologyMedian Eastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group performance statusMedian progression-free survivalClinical ophthalmic examinationLocal ocular therapyCommon presenting symptomProgression-free survivalSite of progressionDiagnosis of lymphomaEyes 12Primary CNSFree survivalIntraocular lymphomaPresenting symptomBrain lymphomaImmunocompetent patientsOcular involvementPerformance statusRetinal biopsy